Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA

NCT06084884 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06084884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06084884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 14, 2023
Completion date
December 13, 2027
Enrollment
94 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma